76 research outputs found
Optimized adenoviral vector that enhances the assembly of FMDV O1 virus-like particles in situ increases its potential as vaccine for serotype O viruses
Although replication-defective human adenovirus type 5 (Ad5) vectors that express in situ the capsid-encoding region of foot-and-mouth disease virus (FMDV) have been proven to be effective as vaccines in relevant species for several viral strains, the same result was not consistently achieved for the O1/Campos/Brazil/58 strain. In the present study, an optimization of the Ad5 system was explored and was proven to enhance the expression of FMDV capsid proteins and their association into virus-like particles (VLPs). Particularly, we engineered a novel Ad5 vector (Ad5[PVP2]OP) which harbors the foreign transcription unit in a leftward orientation relative to the Ad5 genome, and drives the expression of the FMDV sequences from an optimized cytomegalovirus (CMV) enhancer-promoter as well. The Ad5[PVP2]OP vaccine candidate also contains the amino acid substitutions S93F/Y98F in the VP2 protein coding sequence, predicted to stabilize FMD virus particles. Cells infected with the optimized vector showed an âŒ14-fold increase in protein expression as compared to cells infected with an unmodified Ad5 vector tested in previous works. Furthermore, amino acid substitutions in VP2 protein allowed the assembly of FMDV O1/Campos/Brazil/58 VLPs. Evaluation of several serological parameters in inoculated mice with the optimized Ad5[PVP2]OP candidate revealed an enhanced vaccine performance, characterized by significant higher titers of neutralizing antibodies, as compared to our previous unmodified Ad5 vector. Moreover, 94% of the mice vaccinated with the Ad5[PVP2]OP candidate were protected from homologous challenge. These results indicate that both the optimized protein expression and the stabilization of the in situ generated VLPs improved the performance of Ad5-vectored vaccines against the FMDV O1/Campos/Brazil/58 strain and open optimistic expectations to be tested in target animals.Instituto de VirologĂaFil: Ziraldo, Micaela. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Centro de VirologĂa Animal; ArgentinaFil: Bidart, Juan Esteban. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de VirologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Prato, Cecilia A. Universidad Nacional de San MartĂn. Instituto de Investigaciones BiotecnolĂłgicas. Laboratorio de InmunologĂa Molecular; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Tribulatti, MarĂa Virginia. Universidad Nacional de San MartĂn. Instituto de Investigaciones BiotecnolĂłgicas. Laboratorio de InmunologĂa Molecular; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Zamorano, Patricia Ines. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de VirologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Mattion, Nora Marta. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Centro de VirologĂa Animal; ArgentinaFil: D'Antuono, Alejandra. Centro de VirologĂa Animal; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentin
Protection induced by a glycoprotein E-deleted bovine herpesvirus type 1 marker strain used either as an inactivated or live attenuated vaccine in cattle
BACKGROUND: Bovine herpesvirus type 1 (BoHV-1) is the causative agent of respiratory and genital tract infections; causing a high economic loss in all continents. Use of marker vaccines in IBR eradication programs is widely accepted since it allows for protection of the animals against the disease while adding the possibility of differentiating vaccinated from infected animals.The aim of the present study was the development and evaluation of safety and efficacy of a glycoprotein E-deleted (gE-) BoHV-1 marker vaccine strain (BoHV-1ÎgEÎČgal) generated by homologous recombination, replacing the viral gE gene with the ÎČ-galactosidase (ÎČgal) gene. RESULTS: In vitro growth kinetics of the BoHV-1ÎgEÎČgal virus was similar to BoHV-1 LA. The immune response triggered by the new recombinant strain in cattle was characterized both as live attenuated vaccine (LAV) and as an inactivated vaccine. BoHV-1ÎgEÎČgal was highly immunogenic in both formulations, inducing specific humoral and cellular immune responses. Antibody titers found in animals vaccinated with the inactivated vaccine based on BoHV-1ÎgEÎČgal was similar to the titers found for the control vaccine (BoHV-1 LA). In the same way, titers of inactivated vaccine groups were significantly higher than any of the LAV immunized groups, independently of the inoculation route (pâ<â0.001). Levels of IFN-Îł were significantly higher (pâ<â0.001) in those animals that received the LAV compared to those that received the inactivated vaccine. BoHV-1ÎgEÎČgal exhibited an evident attenuation when administered as a LAV; no virus was detected in nasal secretions of vaccinated or sentinel animals during the post-vaccination period. BoHV-1ÎgEÎČgal, when used in either formulation, elicited an efficient immune response that protected animals against challenge with virulent wild-type BoHV-1. Also, the deletion of the gE gene served as an immunological marker to differentiate vaccinated animals from infected animals. All animals vaccinated with the BoHV-1ÎgE ÎČgal strain were protected against disease after challenge and shed significantly less virus than control calves, regardless of the route and formulation they were inoculated. CONCLUSIONS: Based on its attenuation, immunogenicity and protective effect after challenge, BoHV-1ÎgEÎČgal virus is an efficient and safe vaccine candidate when used either as inactivated or as live attenuated forms.Fil: Romera, Sonia. Instituto Nacional de Tecnologia Agropecuaria. Centro Nacional de Investigaciones Agropecuarias. Centro de InvestigaciĂłn de Ciencias Veterinarias y Agronomicas; Argentina. Universidad del Salvador; ArgentinaFil: Puntel, Mariana. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. FundaciĂłn Instituto Leloir; ArgentinaFil: Quattrocchi, Valeria. Instituto Nacional de Tecnologia Agropecuaria. Centro Nacional de Investigaciones Agropecuarias. Centro de InvestigaciĂłn de Ciencias Veterinarias y Agronomicas; ArgentinaFil: del Medico Zajac, Maria Paula. Instituto Nacional de Tecnologia Agropecuaria. Centro Nacional de Investigaciones Agropecuarias. Centro de InvestigaciĂłn de Ciencias Veterinarias y Agronomicas; ArgentinaFil: Zamorano, Patricia Ines. Instituto Nacional de Tecnologia Agropecuaria. Centro Nacional de Investigaciones Agropecuarias. Centro de InvestigaciĂłn de Ciencias Veterinarias y Agronomicas; Argentina. Universidad del Salvador; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Blanco Viera, Javier. Instituto Nacional de Tecnologia Agropecuaria. Centro Nacional de Investigaciones Agropecuarias. Centro de InvestigaciĂłn de Ciencias Veterinarias y Agronomicas; ArgentinaFil: Carrillo, Consuelo. USDA. Plum Island Animal Disease Center; Estados UnidosFil: Chowdhury, Shafiqul. Louisiana State University. Department of Pathobiological Sciences; Estados UnidosFil: Borca, Manuel V.. USDA. Plum Island Animal Disease Center; Estados UnidosFil: Sadir, Ana M.. Instituto Nacional de Tecnologia Agropecuaria. Centro Nacional de Investigaciones Agropecuarias. Centro de InvestigaciĂłn de Ciencias Veterinarias y Agronomicas; Argentina. Universidad del Salvador; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentin
A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine
Foot-and-Mouth Disease (FMD) is an acute viral disease that causes important economy losses. Vaccines with new low-cost adjuvants that stimulate protective immune responses are needed and can be assayed in a mouse model to predict their effectiveness in cattle. Immunostimulant Particle Adjuvant (ISPA), also known as cage-like particle adjuvant, consisting of lipid boxes of dipalmitoyl-phosphatidylcholine, cholesterol, sterylamine, alpha-tocopherol, and QuilA saponin, was shown to enhance protection of a recombinant vaccine against Trypanosoma cruzi in a mouse model. Thus, in the present work, we studied the effects on the magnitude and type of immunity elicited in mice and cattle in response to a vaccine based on inactivated FMD virus (iFMDV) formulated with ISPA. It was demonstrated that iFMDVâISPA induced protection in mice against challenge and elicited a specific antibody response in sera, characterized by a balanced Th1/Th2 profile. In cattle, the antibody titers reached corresponded to an expected percentage of protection (EPP) higher than 80%. EPP calculates the probability that livestock would be protected against a 10,000 bovine infectious doses challenge after vaccination. Moreover, in comparison with the non-adjuvanted iFMDV vaccine, iFMDVâISPA elicited an increased specific T-cell response against the virus, including higher interferon gamma (IFNÎł)+/CD8+ lymphocyte production in cattle. In this work, we report for first time that an inactivated FMDV serotype A vaccine adjuvanted with ISPA is capable of inducing protection against challenge in a murine model and of improving the specific immune responses against the virus in cattle.Fil: Bidart, Juan Esteban. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Kornuta, Claudia Alejandra. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Gammella, Mariela Vanesa. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Gnazzo, Victoria. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - Nordeste. Instituto de BiologĂa Subtropical. Instituto de BiologĂa Subtropical - Nodo Puerto IguazĂș | Universidad Nacional de Misiones. Instituto de BiologĂa Subtropical. Instituto de BiologĂa Subtropical - Nodo Puerto IguazĂș; ArgentinaFil: Soria, Ivana. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Mongini, Claudia. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Galarza, Roxana. Instituto Nacional de Tecnologia Agropecuaria. Centro Regional Buenos Aires Sur. Estacion Experimental Agropecuaria Cuenca del Salado. Agencia de Extension Rural Chascomus.; ArgentinaFil: Calvinho, Luis Fernando. Instituto Nacional de TecnologĂa Agropecuaria. Centro Regional Santa Fe. EstaciĂłn Experimental Agropecuaria Rafaela; ArgentinaFil: Lupi, Giuliana Antonella. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad Nacional del Litoral; ArgentinaFil: Quattrocchi, Valeria. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Marcipar, IvĂĄn Sergio. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad Nacional del Litoral; ArgentinaFil: Zamorano, Patricia Ines. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; Argentin
Bovine Dendritic Cell Activation, T Cell Proliferation and Antibody Responses to Foot-And-Mouth Disease, Is Similar With Inactivated Virus and Virus Like Particles
Foot-and-mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals that causes severe economic losses in the livestock industry. Currently available vaccines are based on the inactivated FMD virus (FMDV). Although inactivated vaccines have been effective in controlling the disease, they have some disadvantages. Because of these disadvantages, investigations are being made to produce vaccines in low containment facilities. The use of recombinant empty capsids (also referred as Virus Like Particles, VLPs) has been reported to be a promising candidate as a subunit vaccine because it avoids the use of virus in the vaccine production and conserves the conformational epitopes of the virus. Mignaqui and collaborators have produced recombinant FMDV empty capsids from serotype A/ARG/2001 using a scalable technology in mammalian cells that elicited a protective immunity against viral challenge in a mouse model. However, further evaluation of the immune response elicited by these VLPs in cattle is required. In the present work we compare the effect that VLPs or inactivated FMDV has on bovine dendritic cells and the humoral response elicited in cattle after a single vaccination.Fil: Quattrocchi, Valeria. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Bidart, Juan Esteban. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Mignaqui, Ana Clara. Instituto Nacional de TecnologĂa Agropecuaria. Centro Regional Patagonia Norte. EstaciĂłn Experimental Agropecuaria San Carlos de Bariloche. Instituto de Investigaciones Forestales y Agropecuarias Bariloche. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - Patagonia Norte. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; ArgentinaFil: Ruiz, Vanesa. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Ferella, Alejandra. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Gammella, Mariela Vanesa. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Ferraris, Sergio RaĂșl. Universidad MaimĂłnides; ArgentinaFil: Carrillo, Jorge. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn de Agroindustria; ArgentinaFil: Wigdorovitz, AndrĂ©s. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; ArgentinaFil: Durocher, Yves. National Research Council; CanadĂĄFil: Cardillo, Sabrina Beatriz. Biogenesis Bago S.a..; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Charleston, Bryan. The Pirbright Institute; Reino UnidoFil: Zamorano, Patricia Ines. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; Argentin
MANα1-2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHV-1
New technologies in the field of vaccinology arise as a necessity for the treatment and control of many diseases. Whole virus inactivated vaccines and modified live virus ones used against Bovine Herpesvirus-1 (BoHV-1) infection have several disadvantages. Previous works on DNA vaccines against BoHV-1 have demonstrated the capability to induce humoral and cellular immune responses. Nevertheless, ânakedâ DNA induces low immunogenic response. Thus, loading of antigen encoding DNA sequences in liposomal formulations targeting dendritic cell receptors could be a promising strategy to better activate these antigen-presenting cells (APC). In this work, a DNA-based vaccine encoding the truncated version of BoHV-1 glycoprotein D (pCIgD) was evaluated alone and encapsulated in a liposomal formulation containing LPS and decorated with MANα1-2MAN-PEG-DOPE (pCIgD-Man-L). The vaccinations were performed in mice and bovines. The results showed that the use of pCIgD-Man-L enhanced the immune response in both animal models. For humoral immunity, significant differences were achieved when total antibody titres and isotypes were assayed in sera. Regarding cellular immunity, a significant increase in the proliferative response against BoHV-1 was detected in animals vaccinated with pCIgD-Man-L when compared to the response induced in animals vaccinated with pCIgD. In addition, upregulation of CD40 molecules on the surface of bovine dendritic cells (DCs) was observed when cells were stimulated and activated with the vaccine formulations. When viral challenge was performed, bovines vaccinated with MANα1-2MAN-PEG-DOPE elicited better protection which was evidenced by a lower viral excretion. These results demonstrate that the dendritic cell targeting using MANα1-2MAN decorated liposomes can boost the immunogenicity resulting in a long-lasting immunity. Liposomes decorated with MANα1-2MAN-PEG-DOPE were tested for the first time as a DNA vaccine nanovehicle in cattle as a preventive treatment against BoHV-1. These results open new perspectives for the design of vaccines for the control of bovine rhinotracheitis.Fil: Kornuta, Claudia Alejandra. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn En Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa E Innovaciones TecnolĂłgicas. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Pque. Centenario. Instituto de VirologĂa E Innovaciones TecnolĂłgicas; ArgentinaFil: Bidart, Juan Esteban. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn En Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa E Innovaciones TecnolĂłgicas. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Pque. Centenario. Instituto de VirologĂa E Innovaciones TecnolĂłgicas; ArgentinaFil: Soria, Ivana. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn En Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa E Innovaciones TecnolĂłgicas. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Pque. Centenario. Instituto de VirologĂa E Innovaciones TecnolĂłgicas; ArgentinaFil: Gammella, Mariela Vanesa. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn En Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa E Innovaciones TecnolĂłgicas. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Pque. Centenario. Instituto de VirologĂa E Innovaciones TecnolĂłgicas; ArgentinaFil: Quattrocchi, Valeria. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn En Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa E Innovaciones TecnolĂłgicas. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Pque. Centenario. Instituto de VirologĂa E Innovaciones TecnolĂłgicas; ArgentinaFil: Pappalardo, Juan Sebastian. Instituto Nacional de TecnologĂa Agropecuaria. Centro Regional Patagonia Norte. EstaciĂłn Experimental Agropecuaria San Carlos de Bariloche. Instituto de Investigaciones Forestales y Agropecuarias Bariloche. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - Patagonia Norte. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; ArgentinaFil: Salmaso, Stefano. UniversitĂ di Padova; ItaliaFil: Torchilin, Vladimir P. Northeastern University; Estados UnidosFil: CheuquepĂĄn Valenzuela, Felipe AndrĂ©s. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Instituto Nacional de TecnologĂa Agropecuaria. Centro Regional Buenos Aires Sur. EstaciĂłn Experimental Agropecuaria Balcarce; ArgentinaFil: Hecker, Yanina Paola. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Instituto Nacional de TecnologĂa Agropecuaria. Centro Regional Buenos Aires Sur. EstaciĂłn Experimental Agropecuaria Balcarce; ArgentinaFil: Moore, Dadin Prando. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Instituto Nacional de TecnologĂa Agropecuaria. Centro Regional Buenos Aires Sur. EstaciĂłn Experimental Agropecuaria Balcarce; ArgentinaFil: Zamorano, Patricia Ines. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn En Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa E Innovaciones TecnolĂłgicas. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Pque. Centenario. Instituto de VirologĂa E Innovaciones TecnolĂłgicas; ArgentinaFil: Langellotti, Cecilia Ana. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn En Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa E Innovaciones TecnolĂłgicas. - Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Pque. Centenario. Instituto de VirologĂa E Innovaciones TecnolĂłgicas; Argentin
Recommended from our members
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9â27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6â16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2â1.8), stage II (OR 1.6; 95% CI 1.4â1.9), and stage III or worse (OR 2.8; 95% CI 2.3â3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
Recommended from our members
Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
The original version of this article unfortunately contained a mistake
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9â27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6â16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2â1.8), stage II (OR 1.6; 95% CI 1.4â1.9), and stage III or worse (OR 2.8; 95% CI 2.3â3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
Galectinâ8 activates dendritic cells and stimulates antigenâspecific immune response elicitation
Galectinâ8 (Galâ8) is a mammalian ÎČâgalactosideâbinding lectin, endowed with proinflammatory properties. Given its capacity to enhance antigenâspecific immune responses in vivo, we investigated whether Galâ8 was also able to promote APC activation to sustain T cell activation after priming. Both endogenous [dendritic cells (DCs)] and bone marrowâderived DCs (BMDCs) treated with exogenous Galâ8 exhibited a mature phenotype characterized by increased MHC class II (MHCII), CD80, and CD86 surface expression. Moreover, Galâ8âtreated BMDCs (Galâ8âBMDCs) stimulated antigenâspecific T cells more efficiently than immature BMDCs (iBMDCs). Proinflammatory cytokines ILâ3, ILâ2, ILâ6, TNF, MCPâ1, and MCPâ5, as well as growth factor GâCSF, were augmented in Galâ8âBMDC conditioned media, with ILâ6 as the most prominent. Remarkably, BMDCs from Galâ8âdeficient mice (Lgals8â/â BMDC) displayed reduced CD86 and ILâ6 expression and an impaired ability to promote antigenâspecific CD4 T cell activation. To test if Galâ8âinduced activation correlates with the elicitation of an effective immune response, soluble Galâ8 was coadministrated with antigen during immunization of BALB/cJ mice in the experimental footâandâmouth disease virus (FMDV) model. When a single dose of Galâ8 was added to the antigen formulation, an increased specific and neutralizing humoral response was developed, sufficient to enhance animal protection upon viral challenge. ILâ6 and IFNâÎł, as well as lymphoproliferative responses, were also incremented in Galâ8/antigenâimmunized animals only at 48 h after immunization, suggesting that Galâ8 induces the elicitation of an inflammatory response at an early stage. Taking together, these findings argue in favor of the use of Galâ8 as an immuneâstimulator molecule to enhance the adaptive immune response.Instituto de VirologĂaFil: Carabelli, Julieta. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - La Plata. Instituto de Investigaciones BiotecnolĂłgicas. Universidad Nacional de San MartĂn. Instituto de Investigaciones BiotecnolĂłgicas. Laboratorio de InmunologĂa Molecular; ArgentinaFil: Quattrocchi, Valeria. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de VirologĂa; ArgentinaFil: D'Antuono, Alejandra. Instituto de Ciencias y TecnologĂa âDr. Cesar Milsteinâ. Centro de VirologĂa Animal; ArgentinaFil: Zamorano, Patricia Ines. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de VirologĂa; ArgentinaFil: Tribulatti, MarĂa Virginia. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - La Plata. Instituto de Investigaciones BiotecnolĂłgicas. Universidad Nacional de San MartĂn. Instituto de Investigaciones BiotecnolĂłgicas. Laboratorio de InmunologĂa Molecular; ArgentinaFil: Campetella, Oscar Eduardo. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - La Plata. Instituto de Investigaciones BiotecnolĂłgicas. Universidad Nacional de San MartĂn. Instituto de Investigaciones BiotecnolĂłgicas. Laboratorio de InmunologĂa Molecular; Argentin
Co-inoculation of baculovirus and FMDV vaccine in mice, elicits very early protection against foot and mouth disease virus without interfering with long lasting immunity
Baculoviruses (Bvs) potentiate the immune response against soluble antigens. We investigated whether Bv could be used as immunoactivator in foot-and-mouth disease (FMD) vaccines using the BALB/c mouse model. Mice were vaccinated with a single dose of inactivated FMDV (iFMDV), iFMDV. +. Bv, Bv, or culture medium. Humoral and cellular immune responses were higher in animals immunized with iFMDV. +. Bv than in mice vaccinated with iFMDV alone. Animals receiving iFMDV. +. Bv had significantly lower viremia at 2, 4 and 7. dpv, than those immunized with iFMDV alone. In order to prolong the immune response, iFMDV oil vaccine was co-inoculated with Bv. Animals receiving iFMDV oil vaccine. +. Bv were protected two days earlier than those receiving the iFMDV oil vaccine alone. Both formulations protected until 14. dpv, the last day of the experiment.This is the first report in which Bv is used as an adjuvant in a FMDV vaccine.Fil: Quattrocchi, Valeria. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn en Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa; ArgentinaFil: Molinari, Maria Paula. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad del Salvador; ArgentinaFil: Langellotti, Cecilia Ana. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad del Salvador; ArgentinaFil: Gnazzo, Victoria. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad del Salvador; ArgentinaFil: Taboga, Oscar Alberto. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn en Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa; ArgentinaFil: Zamorano, Patricia Ines. Instituto Nacional de TecnologĂa Agropecuaria. Centro de InvestigaciĂłn en Ciencias Veterinarias y AgronĂłmicas. Instituto de VirologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentin
- âŠ